
Sign up to save your podcasts
Or


The first half of 2025 was decidedly mixed for many publicly traded healthcare companies, and they’re facing murky waters in the back half of the year amid policy and cost upheaval.
In this episode of "Podnosis," Fierce Healthcare Associate Editor Dave Muoio and Senior Writer Paige Minemyer break down the topline takeaways from another round of corporate earnings calls, including a look at executive commentary on the “big, beautiful” policy environment.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.
By Fierce Healthcare4.7
33 ratings
The first half of 2025 was decidedly mixed for many publicly traded healthcare companies, and they’re facing murky waters in the back half of the year amid policy and cost upheaval.
In this episode of "Podnosis," Fierce Healthcare Associate Editor Dave Muoio and Senior Writer Paige Minemyer break down the topline takeaways from another round of corporate earnings calls, including a look at executive commentary on the “big, beautiful” policy environment.
To learn more about the topics in this episode:
See omnystudio.com/listener for privacy information.

4,887 Listeners

4,363 Listeners

1,097 Listeners

30,240 Listeners

2,383 Listeners

346 Listeners

56,599 Listeners

225 Listeners

497 Listeners

9,533 Listeners

340 Listeners

203 Listeners

388 Listeners

692 Listeners

173 Listeners